Vivo Capital LLC Acquires New Shares in enGene Holdings Inc. (NASDAQ:ENGN)

Vivo Capital LLC bought a new stake in shares of enGene Holdings Inc. (NASDAQ:ENGN - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 678,705 shares of the company's stock, valued at approximately $6,264,000. Vivo Capital LLC owned approximately 2.93% of enGene at the end of the most recent reporting period.

Insiders Place Their Bets

In other news, major shareholder De Solidarite Des Travai Fonds sold 47,854 shares of the firm's stock in a transaction dated Monday, April 22nd. The stock was sold at an average price of $15.00, for a total transaction of $717,810.00. Following the sale, the insider now directly owns 3,036,153 shares in the company, valued at approximately $45,542,295. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 13.70% of the company's stock.

Analysts Set New Price Targets

ENGN has been the topic of several research analyst reports. Wells Fargo & Company started coverage on enGene in a research note on Monday, April 22nd. They set an "overweight" rating and a $30.00 price target on the stock. Leerink Partnrs restated an "outperform" rating on shares of enGene in a research note on Tuesday, February 20th. SVB Leerink began coverage on shares of enGene in a research note on Tuesday, February 20th. They issued an "outperform" rating and a $31.00 price objective on the stock. Guggenheim initiated coverage on shares of enGene in a research report on Monday, April 15th. They set a "buy" rating and a $34.00 target price for the company. Finally, Morgan Stanley began coverage on enGene in a research report on Friday, March 8th. They set an "overweight" rating and a $40.00 price target on the stock. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock has a consensus rating of "Buy" and an average price target of $34.40.

enGene Price Performance

Shares of ENGN traded down $0.12 during trading hours on Thursday, hitting $14.40. The stock had a trading volume of 8,339 shares, compared to its average volume of 58,439. The business's 50-day moving average is $16.17. enGene Holdings Inc. has a fifty-two week low of $6.69 and a fifty-two week high of $43.00.

enGene Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.